ICON Public Limited Company Share Price

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 20/05/2024 BST 5-day change 1st Jan Change
318.7 USD +1.27% Intraday chart for ICON Public Limited Company +2.98% +12.59%
Sales 2024 * 8.64B 680B Sales 2025 * 9.28B 731B Capitalization 26.35B 2,074B
Net income 2024 * 820M 64.53B Net income 2025 * 1B 78.7B EV / Sales 2024 * 3.31 x
Net Debt 2024 * 2.29B 180B Net Debt 2025 * 1.13B 88.93B EV / Sales 2025 * 2.96 x
P/E ratio 2024 *
32.2 x
P/E ratio 2025 *
26.5 x
Employees 41,150
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.27%
1 week+2.98%
Current month+7.00%
1 month+10.58%
3 months+12.43%
6 months+18.04%
Current year+12.59%
More quotes
1 week
312.44
Extreme 312.4401
322.59
1 month
288.23
Extreme 288.23
322.59
Current year
244.59
Extreme 244.59
344.77
1 year
201.35
Extreme 201.35
344.77
3 years
171.43
Extreme 171.43
344.77
5 years
104.28
Extreme 104.275
344.77
10 years
40.00
Extreme 40
344.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 31/10/11
Director of Finance/CFO 45 31/12/05
Chairman 61 02/10/05
Members of the board TitleAgeSince
Founder 71 31/05/90
Chief Executive Officer 63 31/10/11
Director/Board Member 68 30/06/21
More insiders
Date Price Change Volume
20/05/24 318.7 +1.27% 358,620
17/05/24 314.7 -0.35% 224,336
16/05/24 315.8 -1.86% 247,399
15/05/24 321.8 +1.97% 509,291
14/05/24 315.6 +1.96% 474,970

Delayed Quote Nasdaq, May 20, 2024 at 09:00 pm

More quotes
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
318.7 USD
Average target price
354.1 USD
Spread / Average Target
+11.11%
Consensus